Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma

被引：0
|
作者：
Wen, P. Y. [1 ]
Shih, K. [2 ]
Schiff, D. [3 ]
Brachmann, R. [4 ]
Weitzman, R. [4 ]
Cloughesy, T. [5 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Sarah Cannon Res Insititute, Neurooncol, Nashville, TN USA
[3] Univ Virginia Hlth Syst, Neurol, Charlottesville, VA USA
[4] BeiGene USA Inc, Clin Dev, Emeryville, CA USA
[5] Univ Calif Los Angeles, Neurol Oncol, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)
    Sahai, V.
    Chang, A.
    Crysler, O.
    Zhen, D.
    Luther, S.
    Zalupski, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S160 - S160
  • [42] A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
    Sahai, Vaibhav
    Chang, Amy E.
    Crysler, Oxana V.
    Zhen, David Bing
    Beg, Muhammad Shaalan
    Pardee, Timothy S.
    Luther, Sanjeev
    Griffith, Kent A.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.
    Lee, Keun-Seok
    Wang, Xiaojia
    Im, Young Hyuck
    Zeng, Xiaohua
    Li, Huiping
    Wang, Kun
    Li, Huiyan
    Zhou, Ping
    Bao, Yuanyuan
    Jiang, Zefei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study
    Wang, Xiaojia
    Lee, Keun Seok
    Zeng, Xiaohua
    Sun, Tao
    Im, Young-Hyuck
    Li, Huiping
    Wang, Kun
    Li, Huiyan
    Zhou, Ping
    Bao, Yuanyuan
    Jiang, Zefei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Phase 1b/2 Study of the First-in-Class SUMOActivating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with TripleClass Refractory Multiple Myeloma
    Lonial, Sagar
    Tarantolo, Stefano R.
    Boccia, Ralph V.
    Yimer, Habte
    Levy, Moshe Y.
    Abonour, Rafat
    Mohan, Meera
    Roy, Vivek
    Larsen, Jeremy T.
    Girnius, Saulius K.
    Rosenbaum, Cara A.
    Nadeem, Omar
    Berg, Deborah
    Chao, Bo
    Berger, Allison J.
    Nakamura, Akito
    Zhang, Yuhong
    Song, Keli
    Ward, Christine K.
    Proscurshim, Igor
    Kumar, Shaji
    BLOOD, 2021, 138
  • [46] Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
    Jia, Ru
    Si, Hai-Yan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Wang, Yanrong
    Fan, Meng-Jiao
    Miao, Meng-Meng
    Zhang, Bei
    Tong, Shuang
    Dai, Guang-Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 671 - 671
  • [47] Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis
    Burns, Chris
    Cock, Terrie-Anne
    Bishop, Anthony
    Kruger, Nicole
    McCormack, Sarah
    Ananda, Sumitra
    Harris, Marion
    Joubert, Warren Lance
    Kim, Jin Won
    Lee, Choong-kun
    Lee, Woo Jin
    Lipton, Larissa Rachel
    Nagrial, Adnan
    Oh, Do-Youn
    Park, Joon Oh
    Pavlakis, Nick
    Lickliter, Jason
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer
    Gradishar, W. J.
    Kaklamani, V
    Sahoo, Prasad T.
    Lokanatha, D.
    Raina, V
    Bondarde, S.
    Jain, M.
    CANCER RESEARCH, 2009, 69 (24) : 496S - 496S
  • [49] Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis
    Cock, Terrie-Anne
    Bishop, Anthony
    Kruger, Nicole
    McCormack, Sarah
    Harris, Marion
    Ananda, Sumitra
    Lipton, Lara
    Nagrial, Adnan
    Pavlakis, Nick
    Joubert, Warren
    Donato, Laura
    Lickliter, Jason
    Burns, Christopher
    CANCER RESEARCH, 2024, 84 (07)
  • [50] Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/nab-paclitaxel.
    Kim, Seung Tae
    Hong, Jung Yong
    Park, Young Suk
    Kim, Seong-Jin
    Park, Joon Oh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16299 - E16299
12345